$ACON
Aclarion, Inc.

2024 Q2 Form 10-Q Financial Statement

#000168316824003506 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $10.97K $10.11K $25.47K
YoY Change -35.74% -60.29% 182.18%
Cost Of Revenue $23.29K $19.48K $17.45K
YoY Change 20.69% 11.61% 4.29%
Gross Profit -$12.32K -$9.362K $8.020K
YoY Change 452.85% -216.73% -204.07%
Gross Profit Margin -112.32% -92.56% 31.49%
Selling, General & Admin $921.1K $1.027M $984.9K
YoY Change -20.18% 4.27% 75.69%
% of Gross Profit 12280.3%
Research & Development $202.1K $239.0K $204.4K
YoY Change -19.16% 16.95% -0.2%
% of Gross Profit 2548.63%
Depreciation & Amortization $45.76K $45.11K $39.37K
YoY Change 13.16% 14.58% -16.94%
% of Gross Profit 490.9%
Operating Expenses $1.123M $1.266M $1.189M
YoY Change -20.0% 6.45% 55.38%
Operating Profit -$1.136M -$1.275M -$1.181M
YoY Change -19.25% 7.96% 52.8%
Interest Expense -$102.5K $335.8K -$1.380K
YoY Change -317.42% -24435.07% -100.85%
% of Operating Profit
Other Income/Expense, Net -$102.5K -$1.124M -$820.00
YoY Change 75.67% 136948.17% 228.0%
Pretax Income -$1.238M -$2.399M -$1.183M
YoY Change -15.46% 102.72% 26.43%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.238M -$2.399M -$1.183M
YoY Change -15.46% 102.72% 26.43%
Net Earnings / Revenue -11285.0% -23720.61% -4646.49%
Basic Earnings Per Share -$0.15 -$0.44 -$0.15
Diluted Earnings Per Share -$0.15 -$0.44 -$0.15
COMMON SHARES
Basic Shares Outstanding 8.204M shares 7.154M shares 7.862M shares
Diluted Shares Outstanding 8.217M shares 5.443M shares 7.939M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.223M $2.183M $450.0K
YoY Change 103.78% 385.03% 791.97%
Cash & Equivalents $1.173M $2.133M $458.0K
Short-Term Investments $50.00K $50.00K
Other Short-Term Assets $609.4K $338.3K $210.0K
YoY Change 238.53% 61.1% -58.21%
Inventory
Prepaid Expenses
Receivables $19.71K $17.21K $17.15K
Other Receivables $0.00 $160.00 $0.00
Total Short-Term Assets $1.852M $2.538M $675.5K
YoY Change 132.02% 275.75% 19.46%
LONG-TERM ASSETS
Property, Plant & Equipment $1.189K $1.486K $2.843K
YoY Change -49.23% -47.73% -73.96%
Goodwill
YoY Change
Intangibles $1.236M $1.187M $1.183M
YoY Change 2.64% 0.37%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.237M $1.189M $1.186M
YoY Change 2.54% 0.26% -4.56%
TOTAL ASSETS
Total Short-Term Assets $1.852M $2.538M $675.5K
Total Long-Term Assets $1.237M $1.189M $1.186M
Total Assets $3.089M $3.727M $1.861M
YoY Change 54.1% 100.24% 2.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $179.1K $195.7K $544.7K
YoY Change -70.52% -64.07% -60.73%
Accrued Expenses $448.0K $288.1K $190.0K
YoY Change 191.26% 51.65% -84.18%
Deferred Revenue
YoY Change
Short-Term Debt $777.1K $670.2K $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.447M $1.222M $736.4K
YoY Change -27.46% 65.92% -91.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.447M $1.222M $736.4K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.447M $1.222M $740.0K
YoY Change -27.3% 65.11% -91.53%
SHAREHOLDERS EQUITY
Retained Earnings -$47.92M -$46.68M -$40.55M
YoY Change 14.04% 15.11% 22.48%
Common Stock $82.00 $72.00 $79.00
YoY Change 0.0% -8.86% 777.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.642M $2.505M $1.125M
YoY Change
Total Liabilities & Shareholders Equity $3.089M $3.727M $1.861M
YoY Change 54.1% 100.24% 2.96%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$1.238M -$2.399M -$1.183M
YoY Change -15.46% 102.72% 26.43%
Depreciation, Depletion And Amortization $45.76K $45.11K $39.37K
YoY Change 13.16% 14.58% -16.94%
Cash From Operating Activities -$1.055M -$2.239M -$1.013M
YoY Change 11.29% 120.96% 290.52%
INVESTING ACTIVITIES
Capital Expenditures $93.82K $63.66K $11.72K
YoY Change 54.03% 443.17% -108.84%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$93.82K -$63.66K -$11.72K
YoY Change 54.03% 443.15% -91.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 188.4K $3.414M 0.000
YoY Change -83.82%
NET CHANGE
Cash From Operating Activities -1.055M -$2.239M -1.013M
Cash From Investing Activities -93.82K -$63.66K -11.72K
Cash From Financing Activities 188.4K $3.414M 0.000
Net Change In Cash -959.9K $1.112M -1.025M
YoY Change -713.15% -208.46% 161.38%
FREE CASH FLOW
Cash From Operating Activities -$1.055M -$2.239M -$1.013M
Capital Expenditures $93.82K $63.66K $11.72K
Free Cash Flow -$1.148M -$2.302M -$1.025M
YoY Change 13.87% 124.64% 708.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q1 ACON Cashless Exercise Of Prefunded Warrants
CashlessExerciseOfPrefundedWarrants
usd
CY2024Q1 ACON Round Up Convention Related To Reverse Stock Split
RoundUpConventionRelatedToReverseStockSplit
usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49186006 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46680628 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2505450 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3727262 usd
CY2024Q1 us-gaap Revenues
Revenues
10114 usd
CY2023Q1 us-gaap Revenues
Revenues
25470 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
19476 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
17453 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
-9362 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
8017 usd
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
181056 usd
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
177284 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
239042 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
204399 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
845847 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
807599 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
1265945 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1189281 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1275307 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1181264 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
335824 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
1380 usd
CY2024Q1 ACON Loss On Exchange Of Debt
LossOnExchangeOfDebt
1066732 usd
CY2023Q1 ACON Loss On Exchange Of Debt
LossOnExchangeOfDebt
-0 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-111928 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
297684 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
93005 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-816 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1123795 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2196 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2399102 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1183460 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2399102 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1183460 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2399102 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1183460 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.39
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.39
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5442625 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5442625 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
496159 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
496159 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2225958 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
82531 usd
CY2023Q1 ACON Preferred Stock Issued During Period Value New Issues
PreferredStockIssuedDuringPeriodValueNewIssues
1000 usd
CY2023Q1 us-gaap Preferred Stock Redemption Premium
PreferredStockRedemptionPremium
1000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1183460 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1125029 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-727995 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85827 usd
CY2024Q1 ACON Issuance Of Common Stock And Warrants Related To Public Offering Net Issuance Costs Value
IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsValue
2691391 usd
CY2024Q1 ACON Issuance Of Common Shares Equity Line
IssuanceOfCommonSharesEquityLine
1449532 usd
CY2024Q1 ACON Public Offering And Equity Line Issuance Costs
PublicOfferingAndEquityLineIssuanceCosts
-399106 usd
CY2024Q1 ACON Issuance Of Common Shares Debt For Equity Exchange
IssuanceOfCommonSharesDebtForEquityExchange
1771606 usd
CY2024Q1 ACON Issuance Of Commitment Shares Note Financing
IssuanceOfCommitmentSharesNoteFinancing
33297 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2399102 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2505450 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2399102 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1183460 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45109 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39368 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
85827 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
82531 usd
CY2024Q1 ACON Gain Loss On Exchange Of Debt
GainLossOnExchangeOfDebt
1066732 usd
CY2023Q1 ACON Gain Loss On Exchange Of Debt
GainLossOnExchangeOfDebt
0 usd
CY2024Q1 ACON Gains Losses On Extinguishment Of Debts
GainsLossesOnExtinguishmentOfDebts
111928 usd
CY2023Q1 ACON Gains Losses On Extinguishment Of Debts
GainsLossesOnExtinguishmentOfDebts
0 usd
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
335352 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 usd
CY2024Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-297684 usd
CY2023Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2616 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1416 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
134760 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
705 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-640163 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
82540 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-409180 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-34804 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2238557 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1013113 usd
CY2024Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
63657 usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
11719 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-63657 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11719 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2691391 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2024Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1449532 usd
CY2023Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 usd
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
300974 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
CY2024Q1 ACON Equity Line Of Credit Issuance Costs
EquityLineOfCreditIssuanceCosts
259331 usd
CY2023Q1 ACON Equity Line Of Credit Issuance Costs
EquityLineOfCreditIssuanceCosts
-0 usd
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
143463 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-0 usd
CY2024Q1 ACON Bridge Funding Issuance Costs
BridgeFundingIssuanceCosts
23375 usd
CY2023Q1 ACON Bridge Funding Issuance Costs
BridgeFundingIssuanceCosts
-0 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
1000 usd
CY2024Q1 us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
-0 usd
CY2023Q1 us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
1000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3413780 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1111566 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1024831 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1031069 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1482806 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2142635 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
457975 usd
CY2024Q1 ACON Issuance Of Common Shares In Exchange For Debt
IssuanceOfCommonSharesInExchangeForDebt
1771606 usd
CY2023Q1 ACON Issuance Of Common Shares In Exchange For Debt
IssuanceOfCommonSharesInExchangeForDebt
0 usd
CY2024Q1 ACON Public Offering Accrued Issuance Costs
PublicOfferingAccruedIssuanceCosts
112631 usd
CY2023Q1 ACON Public Offering Accrued Issuance Costs
PublicOfferingAccruedIssuanceCosts
0 usd
CY2024Q1 ACON Equity Line Issuance Costs
EquityLineIssuanceCosts
3413 usd
CY2023Q1 ACON Equity Line Issuance Costs
EquityLineIssuanceCosts
0 usd
CY2024Q1 ACON Issuance Of Bridge Fund Commitment Shares
IssuanceOfBridgeFundCommitmentShares
33297 usd
CY2023Q1 ACON Issuance Of Bridge Fund Commitment Shares
IssuanceOfBridgeFundCommitmentShares
0 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_zJ29tWLz40b1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zKf7Y7PteZM2">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements include some amounts that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and valuation of warrants, warrant and derivative liabilities, and options to purchase shares of the Company's common stock. These estimates may be adjusted as more current information becomes available, and any adjustment could be significant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p id="xdx_84B_eus-gaap--DerivativesReportingOfDerivativeActivity_zlViObzS5p96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_z91chs415lQ1">Derivative Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expenses), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1767372 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
761800 usd
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
10000 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
178381 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
178381 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
178381 usd
CY2024Q1 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
67819 usd
CY2023Q4 us-gaap Fair Value Hedge Liabilities At Fair Value
FairValueHedgeLiabilitiesAtFairValue
410491 usd
CY2024Q1 ACON Exchange And Payoff Of Notes Payable
ExchangeAndPayoffOfNotesPayable
-44988 usd
CY2024Q1 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-297684 usd
CY2024Q1 us-gaap Fair Value Hedge Liabilities At Fair Value
FairValueHedgeLiabilitiesAtFairValue
67819 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
378461 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
245030 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
195714 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
760535 usd
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
288129 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
857722 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2335925 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2272268 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-1148458 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-1103645 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1187467 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1168623 usd
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
44812 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
38865 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
518538 usd
CY2024Q1 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
1187467 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
133786 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2024Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2023Q4 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
296313 usd
CY2023Q4 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
320561 usd
CY2024Q1 us-gaap Notes Payable
NotesPayable
862500 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
2594118 usd
CY2024Q1 ACON Unamortized Discounts And Deferred Financing Costs Warrants
UnamortizedDiscountsAndDeferredFinancingCostsWarrants
0 usd
CY2023Q4 ACON Unamortized Discounts And Deferred Financing Costs Warrants
UnamortizedDiscountsAndDeferredFinancingCostsWarrants
-557582 usd
CY2024Q1 ACON Unamortized Discounts And Deferred Financing Costs Derivative
UnamortizedDiscountsAndDeferredFinancingCostsDerivative
-77583 usd
CY2023Q4 ACON Unamortized Discounts And Deferred Financing Costs Derivative
UnamortizedDiscountsAndDeferredFinancingCostsDerivative
-235628 usd
CY2024Q1 ACON Unamortized Discounts And Deferred Financing Costs Issuance Cost
UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost
-114767 usd
CY2023Q4 ACON Unamortized Discounts And Deferred Financing Costs Issuance Cost
UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost
-675184 usd
CY2024Q1 ACON Unamortized Discounts And Deferred Financing Costs Total
UnamortizedDiscountsAndDeferredFinancingCostsTotal
-192350 usd
CY2023Q4 ACON Unamortized Discounts And Deferred Financing Costs Total
UnamortizedDiscountsAndDeferredFinancingCostsTotal
-1468394 usd
CY2024Q1 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
670150 usd
CY2023Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
1125724 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7153500 shares
CY2024Q1 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
1000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
169456 shares
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-2399102 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1183460 usd
CY2024Q1 ACON Weighted Average Number Of Shares Outstanding Basic1
WeightedAverageNumberOfSharesOutstandingBasic1
5426557 shares
CY2023Q1 ACON Weighted Average Number Of Shares Outstanding Basic1
WeightedAverageNumberOfSharesOutstandingBasic1
491345 shares
CY2024Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
16069 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
4814 shares
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5442625 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5442625 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
496159 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
496159 shares
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10845830 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
404859 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
169456 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.15
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.15
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
147977 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
30.57
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
151474 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
30.69
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
85827 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
82531 usd
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-003506-index-headers.html Edgar Link pending
0001683168-24-003506-index.html Edgar Link pending
0001683168-24-003506.txt Edgar Link pending
0001683168-24-003506-xbrl.zip Edgar Link pending
aclarion_ex3101.htm Edgar Link pending
aclarion_ex3102.htm Edgar Link pending
aclarion_ex3201.htm Edgar Link pending
aclarion_ex3202.htm Edgar Link pending
aclarion_i10q-033124.htm Edgar Link pending
acon-20240331.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
acon-20240331_def.xml Edgar Link unprocessable
acon-20240331_lab.xml Edgar Link unprocessable
acon-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aclarion_i10q-033124_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acon-20240331_cal.xml Edgar Link unprocessable